Mineralys Therapeutics (MLYS) Projected to Post Quarterly Earnings on Tuesday

Key Points

• Mineralys Therapeutics is set to release its Q2 2025 earnings on August 12th, where analysts anticipate a loss of ($0.78) per share.
• Despite a recent increase in stock price by 3.2%, the current market cap of Mineralys Therapeutics stands at approximately $876.35 million.
• Several analysts have varied ratings on the stock, with a consensus target price of $32.25, indicating mixed outlooks among investors.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) is expected to be issuing its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 12th. Analysts expect Mineralys Therapeutics to post earnings of ($0.78) per share for the quarter.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last posted its quarterly earnings results on Monday, May 12th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($1.02) by $0.23. On average, analysts expect Mineralys Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Mineralys Therapeutics Stock Up 3.2%

Shares of NASDAQ MLYS traded up $0.42 during midday trading on Tuesday, hitting $13.45. The stock had a trading volume of 249,707 shares, compared to its average volume of 873,418. Mineralys Therapeutics has a 52 week low of $8.24 and a 52 week high of $18.38. The company has a market cap of $876.35 million, a P/E ratio of -3.62 and a beta of -0.29. The business's 50 day moving average is $14.46 and its 200-day moving average is $13.35.

Wall Street Analyst Weigh In

Several research analysts recently commented on MLYS shares. Guggenheim set a $48.00 price target on shares of Mineralys Therapeutics and gave the stock a "buy" rating in a research note on Wednesday, May 14th. Wall Street Zen cut shares of Mineralys Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, June 14th. HC Wainwright reaffirmed a "buy" rating and set a $42.00 target price on shares of Mineralys Therapeutics in a report on Tuesday, June 17th. Finally, Jefferies Financial Group started coverage on shares of Mineralys Therapeutics in a research note on Tuesday, June 10th. They issued a "hold" rating and a $15.00 price target on the stock. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. According to MarketBeat.com, Mineralys Therapeutics has an average rating of "Hold" and a consensus target price of $32.25.

Insider Buying and Selling

In related news, CEO Jon Congleton sold 15,884 shares of the firm's stock in a transaction dated Friday, July 11th. The stock was sold at an average price of $14.51, for a total transaction of $230,476.84. Following the completion of the transaction, the chief executive officer owned 846,405 shares of the company's stock, valued at $12,281,336.55. This trade represents a 1.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Adam Scott Levy sold 59,925 shares of the company's stock in a transaction dated Wednesday, July 30th. The stock was sold at an average price of $14.76, for a total value of $884,493.00. Following the completion of the transaction, the chief financial officer directly owned 132,934 shares in the company, valued at approximately $1,962,105.84. The trade was a 31.07% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 123,052 shares of company stock valued at $1,803,099 over the last 90 days. 33.24% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Mineralys Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Woodline Partners LP acquired a new stake in shares of Mineralys Therapeutics in the 1st quarter valued at about $757,000. Goldman Sachs Group Inc. raised its stake in shares of Mineralys Therapeutics by 166.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 298,395 shares of the company's stock valued at $4,739,000 after purchasing an additional 186,480 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Mineralys Therapeutics by 4.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company's stock worth $271,000 after acquiring an additional 702 shares during the last quarter. Finally, AQR Capital Management LLC bought a new position in Mineralys Therapeutics during the 1st quarter worth approximately $550,000. Institutional investors and hedge funds own 84.46% of the company's stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.